Barrington Research Weighs in on DENTSPLY SIRONA Q1 Earnings

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Investment analysts at Barrington Research dropped their Q1 2025 earnings per share estimates for shares of DENTSPLY SIRONA in a research note issued to investors on Friday, November 8th. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will post earnings of $0.38 per share for the quarter, down from their previous forecast of $0.51. Barrington Research currently has a “Outperform” rating and a $24.00 target price on the stock. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.84 per share. Barrington Research also issued estimates for DENTSPLY SIRONA’s Q2 2025 earnings at $0.49 EPS, Q3 2025 earnings at $0.52 EPS, Q4 2025 earnings at $0.57 EPS and FY2025 earnings at $1.95 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.02. The business had revenue of $951.00 million during the quarter, compared to the consensus estimate of $939.10 million. DENTSPLY SIRONA had a positive return on equity of 12.62% and a negative net margin of 10.59%. The business’s revenue was up .4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.49 EPS.

Other analysts have also recently issued research reports about the company. StockNews.com upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Leerink Partnrs cut DENTSPLY SIRONA from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Stifel Nicolaus dropped their price objective on DENTSPLY SIRONA from $30.00 to $28.00 and set a “hold” rating for the company in a research report on Thursday, July 18th. Evercore ISI dropped their price objective on DENTSPLY SIRONA from $29.00 to $27.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Finally, Robert W. Baird dropped their price objective on DENTSPLY SIRONA from $31.00 to $24.00 and set a “neutral” rating for the company in a research report on Friday. Six analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, DENTSPLY SIRONA has an average rating of “Hold” and a consensus target price of $29.50.

DENTSPLY SIRONA Trading Up 3.5 %

NASDAQ:XRAY opened at $17.86 on Monday. The company has a market capitalization of $3.62 billion, a PE ratio of -8.63, a price-to-earnings-growth ratio of 0.97 and a beta of 1.02. The company has a quick ratio of 0.87, a current ratio of 1.25 and a debt-to-equity ratio of 0.72. DENTSPLY SIRONA has a 52-week low of $17.21 and a 52-week high of $37.60. The stock has a fifty day simple moving average of $24.68 and a 200-day simple moving average of $25.83.

Institutional Trading of DENTSPLY SIRONA

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Eagle Investment Management LLC grew its holdings in DENTSPLY SIRONA by 33.6% in the 2nd quarter. First Eagle Investment Management LLC now owns 13,069,900 shares of the medical instruments supplier’s stock valued at $325,571,000 after buying an additional 3,283,965 shares during the period. Nuance Investments LLC lifted its stake in shares of DENTSPLY SIRONA by 3.8% in the 2nd quarter. Nuance Investments LLC now owns 10,879,916 shares of the medical instruments supplier’s stock valued at $271,019,000 after purchasing an additional 402,329 shares in the last quarter. Cooke & Bieler LP lifted its stake in shares of DENTSPLY SIRONA by 16.2% in the 2nd quarter. Cooke & Bieler LP now owns 7,506,845 shares of the medical instruments supplier’s stock valued at $186,996,000 after purchasing an additional 1,046,105 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of DENTSPLY SIRONA by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,266,781 shares of the medical instruments supplier’s stock valued at $207,995,000 after purchasing an additional 343,915 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of DENTSPLY SIRONA by 42.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,420,445 shares of the medical instruments supplier’s stock valued at $110,118,000 after purchasing an additional 1,308,411 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.